Page last updated: 2024-12-05
indigotindisulfonate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
indigo carmine (acid form) : A member of the class of indolones obtained by formal 2,2'-oxidative coupling of two molecules of 3-oxo-2,3-dihydroindole-5-sulfonic acids. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 3705 |
| CHEMBL ID | 1091250 |
| CHEBI ID | 90117 |
| SCHEMBL ID | 2727226 |
| SCHEMBL ID | 2732840 |
| SCHEMBL ID | 5455215 |
| MeSH ID | M0515721 |
Synonyms (54)
| Synonym |
|---|
| disodium 5, 5'-indigodisulfonate |
| sodium 5, 5'-indigodisulfonate |
| sodium indigo-5, 5'-bisulfonate |
| 1h-indole-5-sulfonic acid, 2-(1, 3-dihydro-3-oxo-5-sulfo-2h-indol-2-ylidene)-2,3-dihydro-3-oxo-, disodium salt |
| (2z)-3-oxo-2-(3-oxo-5-sulfo-indolin-2-ylidene)indoline-5-sulfonic acid |
| {[.delta.2,2'-biindoline]-5,5'-disulfonic} acid, 3, 3'-dioxo-, disodium salt |
| 5,5'-indigotindisulfonic acid |
| {[.delta.(sup2,2')biindoline]-5,5'-disulfonic} acid, 3,3'-dioxo-, disodium salt |
| 1h-indole-5-sulfonic acid, 2-(1, 3-dihydro-3-oxo-5-sulfo-2h-indol-2-ylidine)-2,3-dihydro-3-oxo-, disodium salt |
| nsc-8646 |
| NCGC00159432-02 |
| NCGC00159432-03 |
| 3,3'-dioxo-2,2'-bis-indolyden-5,5'-disulfonic acid |
| indigotindisulfonate |
| indigo carmine acid |
| blue x |
| saxon blue |
| indigotindisulfonic acid |
| CHEMBL1091250 |
| chebi:90117 , |
| (2e)-3-oxo-2-(3-oxo-5-sulfo-1h-indol-2-ylidene)-1h-indole-5-sulfonic acid |
| dtxsid0044288 , |
| tox21_113169 |
| tox21_113170 |
| dtxcid601022746 |
| cas-483-20-5 |
| 2-(1,3-dihydro-3-oxo-5-sulpho-2h-indol-2-ylidene)-3-oxoindoline-5-sulphonic acid |
| einecs 207-593-7 |
| x7oi7jf73p , |
| 483-20-5 |
| unii-x7oi7jf73p |
| 1h-indole-5-sulfonic acid, 2-(1,3-dihydro-3-oxo-5-sulfo-2h-indol-2-ylidene)-2,3-dihydro-3-oxo- |
| SCHEMBL2727226 |
| SCHEMBL2732840 |
| SCHEMBL5455215 |
| AKOS024386980 |
| (2e)-3-oxo-2-(3-oxo-5-sulfo-1,3-dihydro-2h-indol-2-ylidene)-2,3-dihydro-1h-indole-5-sulfonic acid |
| indigo carmine (acid form) |
| indigo-5,5'-disulfonic acid |
| indigo carmine free acid |
| mfcd00005723 |
| (2e)-3-oxo-2-(3-oxo-5-sulfo-1,3-dihydro-2h-indol-2-ylidene)indoline-5-sulfonic acid |
| DB11577 |
| Q27162327 |
| 3,3'-dioxo-[2,2'-biindolinylidene]-5,5'-disulfonic acid |
| 2-(3-hydroxy-5-sulfo-1h-indol-2-yl)-3-oxoindole-5-sulfonic acid |
| STARBLD0000901 |
| acido indigotindisolfonico |
| acido indigotindisulffonico |
| acido indigotindisulfonico |
| acide indigotindisulfonique |
| (e)-3,3'-dioxo-1h,1'h,3h,3'h-[2,2'-biindolylidene]-5,5'-disulfonic acid |
| EN300-26913798 |
| indigo blue, solubl |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (14)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 15.8489 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 11.2202 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 17.7407 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 22.3872 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 24.3616 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 25.1189 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 21.4061 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743079 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 17.7828 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 89.1251 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 354.8130 | 0.0100 | 39.5371 | 1,122.0200 | AID1479 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 6.3191 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 44.6684 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 28.1838 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID472449 | Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 10 uM relative to control | 2010 | Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8 | Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors. |
| AID284124 | Herbicidal activity against Brassica campestris L assessed as inhibition of rape root growth at 10 ug/ml | 2007 | Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1 | Identification of some novel AHAS inhibitors via molecular docking and virtual screening approach. |
| AID284122 | Inhibition of Arabidopsis thaliana AHAS | 2007 | Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1 | Identification of some novel AHAS inhibitors via molecular docking and virtual screening approach. |
| AID284123 | Herbicidal activity against Brassica campestris L assessed as inhibition of rape root growth at 100 ug/ml | 2007 | Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1 | Identification of some novel AHAS inhibitors via molecular docking and virtual screening approach. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 33.82
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.82) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||